Clinical Trial Update: Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cand5, a small interfering RNA, for diabetic macular edema has completed. The update notes the study assessed safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Cand5 (Cand5 siRNA)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED